BioInvent International

BioInvent inks agreement with Cancer Research U.K., CRT and LLR

Wednesday, January 21, 2015 01:02 PM

BioInvent International, a research-based pharmaceutical company based in Sweden, has reached an agreement with Cancer Research U.K.Cancer Research Technology (CRT), the charity’s development and commercialization arm, and Leukemia & Lymphoma Research (LLR) to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

More... »


BioInvent focuses its business, reduces staff

Tuesday, October 2, 2012 01:54 PM

Sweden-based BioInvent International has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR. It will increase the efforts to create new n‑CoDeR agreements for clinical programs and continue to develop existing partnerships.

More... »


BioInvent reorganizes after TB-402 bust

Friday, June 29, 2012 12:53 PM

BioInvent International, a Swedish research-based pharmaceutical company that focuses on developing antibody drugs, has decided to initiate negotiations with trade unions regarding organizational changes due to halting development of the antithrombotic agent TB‑402.

More... »

ThromboGenics and BioInvent begin brain tumor study

Monday, May 16, 2011 01:09 PM

ThromboGenics and co-development partner BioInvent International report that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334). The trial is for patients with glioblastoma multiforme, the most common and aggressive type of primary brain tumor in humans.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs